M.M.M. Rasenberg

Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization

Katie Paul Friedman, Matthew Gagné, Lit‐Hsin Loo et al. · Toxicological Sciences · 2019 · 245 citations · Full text

Pharmacy, Toxicology, Environmental Toxicology +16

UVCB substances: Methodology for structural description and application to fate and hazard assessment

S. Dimitrov, D. Georgieva, Todor Pavlov et al. · Environmental Toxicology and Chemistry · 2015 · 32 citations

Pharmacy, Chemistry, Analytical Chemistry +12

Integration of new approach methods for the assessment of data-poor chemicals

Katie Paul Friedman, Russell S. Thomas, John F. Wambaugh et al. · Toxicological Sciences · 2025 · 23 citations

Pharmacy, Bioinformatics, Toxicology +17

The impact on classifications for carcinogenicity, mutagenicity, reproductive and specific target organ toxicity after repeated exposure in the first ten years of the REACH regulation

P.G. Karamertzanis, Palmi T. Atlason, Alexis V. Nathanail et al. · Regulatory Toxicology and Pharmacology · 2019 · 10 citations

Pharmacy, Toxicology, Carcinogenesis +15

Finding synergies for the 3Rs – Repeated Dose Toxicity testing: Report from an EPAA Partners' Forum

Charles Laroche, Erwin Annys, Hans Bender et al. · Regulatory Toxicology and Pharmacology · 2019 · 10 citations · Full text

Pharmacy, Toxicology, Comparative Toxicology +12